《大行》大摩降金斯瑞生物科技(01548.HK)目标价至16.5元 续予“增持”评级

阿斯达克财经
Mar 11

摩根士丹利发表研究报告指,金斯瑞生物科技(01548.HK) 发盈警后,已将其2026至30年的盈测下调1%至13%,相应目标价由18.3元下调至16.5元,维持“增持”评级。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-10 16:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10